Skip to Main Content

You might know Jennifer Doudna as the Nobel Prize-winning pioneer of CRISPR genome editing, the subject of Walter Isaacson’s last book, or as a professor at the University of California Berkeley, among other titles. Now she’s adding another to the list: chief science advisor to the Wall Street firm Sixth Street, where she’s expected to help guide investment decisions related to the breakthrough technology she discovered.

Sixth Street manages about $60 billion in assets, and its vice chairman is Marty Chavez, a former C-level executive at Goldman Sachs who’s also on the board of the Broad Institute and serves on the Stanford Medicine Board of Fellows.


Doudna and Chavez joined the “The Readout LOUD” to discuss why they teamed up, where science is heading, and what business Wall Street has in CRISPR in the first place.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.